Elevated locus coeruleus metabolism provides resilience against cognitive decline in preclinical Alzheimer's disease

LC FDG-PET signal is lower in Alzheimer's disease (AD) patients. LC FDG-PET signal is higher in the preclinical stage of AD. We observed less memory decline in those with higher LC FDG-PET signal. Higher LC FDG-PET signal conferred cognitive resilience in preclinical AD.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2024-11-26
DOI
https://doi.org/10.1002/alz.14385
Citations
9
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
2.94

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Elevated locus coeruleus metabolism provides resilience against cognitive decline in preclinical Alzheimer's disease

Heidi I.L. Jacobs, Reisa Anne Sperling, J. Alex Becker, Prokopis C. Prokopiou et al.
9 citations
Alzheimer s & Dementia
Alzheimer's disease research and treatments
2.94
article

Elevated locus coeruleus metabolism provides resilience against cognitive decline in preclinical Alzheimer's disease

Heidi I.L. Jacobs, Reisa Anne Sperling, J. Alex Becker, Prokopis C. Prokopiou, Keith A. Johnson, Bernard Hanseeuw, Joyita Dutta, Elouise A. Koops, Julie C. Price, Maxime Van Egroo, Steven Edward Arnold
article en
9 citations

Abstract

LC FDG-PET signal is lower in Alzheimer's disease (AD) patients. LC FDG-PET signal is higher in the preclinical stage of AD. We observed less memory decline in those with higher LC FDG-PET signal. Higher LC FDG-PET signal conferred cognitive resilience in preclinical AD.

Alzheimer s & DementiaVol. 21(1)
Brigham and Women's Hospital (US), Harvard University (US), University of Massachusetts Amherst (US), Maastricht University (NL), Gordon Center for Medical Imaging (US), Massachusetts General Hospital (US), Athinoula A. Martinos Center for Biomedical Imaging (US)
U.S. Department of Defense, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Massachusetts General Hospital, Biogen, University of Southern California, Meso Scale Diagnostics, Alzheimer's Disease Neuroimaging Initiative, BioClinica, Novartis Pharmaceuticals Corporation, Northern California Institute for Research and Education, Eisai, Centre d'Imagerie BioMédicale, Servier, H. Lundbeck A/S, IXICO, National Institutes of Health, Genentech, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Canadian Institutes of Health Research, National Institute of Biomedical Imaging and Bioengineering
Openalex Percentile: Top 8%
Alzheimer's disease research and treatments
2.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.